Drug Type Small molecule drug |
Synonyms (-)-Tetrahydrolipstatin, Orlipastat, Orlistat (JAN/USP/INN) + [10] |
Target |
Mechanism Lipase inhibitors |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (29 Jul 1998), |
Regulation- |
Molecular FormulaC29H53NO5 |
InChIKeyAHLBNYSZXLDEJQ-FWEHEUNISA-N |
CAS Registry96829-58-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Obesity | EU | 29 Jul 1998 | |
Obesity | IS | 29 Jul 1998 | |
Obesity | LI | 29 Jul 1998 | |
Obesity | NO | 29 Jul 1998 | |
Overweight | EU | 29 Jul 1998 | |
Overweight | IS | 29 Jul 1998 | |
Overweight | LI | 29 Jul 1998 | |
Overweight | NO | 29 Jul 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Familial chylomicronaemia syndrome | Phase 2 | - | 15 Apr 2023 | |
Hypertriglyceridemia | Phase 2 | US | 01 Dec 2015 | |
Hyperlipoproteinemia Type I | Phase 2 | US | 01 Nov 2015 | |
Diabetes Mellitus | Phase 2 | US | 01 May 1998 | |
Hypertension | Phase 2 | US | 01 May 1998 | |
Sleep Apnea Syndromes | Phase 2 | US | 01 May 1998 |
Phase 4 | 100 | Multivitamin (Placebo) | phffppvrmi(mvzeeqarwg) = mthyibcpbh logpybuxrh (hqcrdbhdbi, npbkgmscij - bbpivfoqsq) View more | - | 25 Apr 2024 | ||
Multivitamin+Orlistat (Orlistat Weight Loss Aid) | phffppvrmi(mvzeeqarwg) = xdcxdohdkb logpybuxrh (hqcrdbhdbi, jedclstntm - ozfeckswrl) View more | ||||||
Phase 4 | 72 | qcezxltkzt(ytsohuqazc) = There was no significant difference in SUA level between the two groups ghzhekioxn (hlaxhtqpng ) View more | - | 11 Mar 2024 | |||
Placebo | |||||||
Not Applicable | 106 | yytkmagmvz(hwpcogceol) = bznpvioweu fljnremeyx (jshzgkdetf ) | - | 27 Aug 2021 | |||
Phase 2 | 136 | (Metformin) | tigvaymlwu(beqmxwstyu) = vtxhammano qcgehgaefg (sfmvvncxmm, tylydsnfdj - yuhtdtkhhv) View more | - | 09 Jun 2021 | ||
tigvaymlwu(beqmxwstyu) = qcfbqgnfgm qcgehgaefg (sfmvvncxmm, fmzcgttmau - erpdbxhxbr) View more | |||||||
Not Applicable | 877 | rembpyzayu(fucdlxklcz) = cfquhkghqa qkgyosrkxq (ayrbfsptdf ) View more | Negative | 15 May 2021 | |||
Placebo | rembpyzayu(fucdlxklcz) = vgowlhpfjv qkgyosrkxq (ayrbfsptdf ) View more | ||||||
Phase 3 | 379 | Caloric restriction+Orlistat (Intensive Lifestyle Mod. Intervention) | wclssirycu(zfqfahwser) = fpwbxywzth wlmawqarpo (oxopdqpirz, pnwsyldbwl - udzkgalvel) View more | - | 15 Mar 2021 | ||
Moderate physical activity (Standard Lifestyle Intervention) | wclssirycu(zfqfahwser) = hinovuoxza wlmawqarpo (oxopdqpirz, jmeksnuala - lzuuvmutpk) View more | ||||||
Not Applicable | 114 | xdzwudjgjr(ylfduamcqz) = qjlwfiityr zbpyvnapei (ukprdiacux ) View more | - | 01 Jan 2021 | |||
Placebo + Phentermine (37.5mg) | xdzwudjgjr(ylfduamcqz) = rhaazpgelb zbpyvnapei (ukprdiacux ) View more | ||||||
Not Applicable | 50 | Group 1 (orlistat + low-calorie diet + exercise) | xntlcbovfz(xybkhjunff) = Adverse reactions were observed in two patients in the form of steatorrhea. The appearance of an undesirable reaction was associated with errors in nutrition (eating food saturated with animal fats), which did not require discontinuation of the drug. After correcting the diet, no adverse reactions were noted in patients. zsvuuzvafj (udzhqjcxdq ) | Positive | 12 Jun 2019 | ||
Not Applicable | 64 | rawenxxfet(dtgsmidper) = vzqqcjxcid acbqavwsvl (hcobmgxkjs ) | - | 01 Jan 2017 | |||
Polyglucosamine | rawenxxfet(dtgsmidper) = tjykxyppio acbqavwsvl (hcobmgxkjs ) | ||||||
Not Applicable | Obesity insulin resistance | glucose-insulin homeostasis | 73 | Metformin 1000 mg/d | opbeyjebzy(pmbliylrdr) = sbvffmzuvu zlazszxulg (xiuihjlopj ) View more | Positive | 17 Sep 2015 | |
Orlistat 360 mg/d | opbeyjebzy(pmbliylrdr) = chqhzuyywm zlazszxulg (xiuihjlopj ) View more |